We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00463762
Recruitment Status : Withdrawn
First Posted : April 20, 2007
Last Update Posted : April 22, 2011
Sponsor:
Information provided by:
Pfizer

Brief Summary:
The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Condition or disease Intervention/treatment Phase
Abscess, Intra-Abdominal Cholecystitis Wound Infections Peritonitis Appendicitis Drug: CP-75385-02 Cefoperazone/sulbactam Phase 4

Study Type : Observational
Actual Enrollment : 0 participants
Time Perspective: Prospective
Official Title: Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.
Study Start Date : May 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patient of age 18 years or older.
  • Patient with intraabdominal/hepatobiliary infection.?

Exclusion Criteria:

  • Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00463762


Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
ClinicalTrials.gov Identifier: NCT00463762     History of Changes
Other Study ID Numbers: A1891004
First Posted: April 20, 2007    Key Record Dates
Last Update Posted: April 22, 2011
Last Verified: April 2011

Additional relevant MeSH terms:
Infection
Communicable Diseases
Appendicitis
Wound Infection
Peritonitis
Cholecystitis
Acalculous Cholecystitis
Abdominal Abscess
Intraabdominal Infections
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Cecal Diseases
Intestinal Diseases
Peritoneal Diseases
Gallbladder Diseases
Biliary Tract Diseases
Abscess
Suppuration
Sulbactam
Cefoperazone
Sulperazone
Anti-Bacterial Agents
Anti-Infective Agents
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Urinary
Renal Agents